Join the Liraglutide group to help and get support from people like you.
Liraglutide News
Exercise + GLP-1 RA Effective for Weight Loss While Preserving BMD
THURSDAY, June 27, 2024 – For adults with obesity, without diabetes, combining exercise with the glucagon-like peptide-1 receptor agonist (GLP-1 RA), liraglutide, is effective for weight loss, while...
Aspiration Pneumonia Risk Increased for GLP-1 RA Users Undergoing Endoscopy
FRIDAY, April 12, 2024 – Patients using glucagon-like peptide 1 receptor agonists (GLP-1 RAs) undergoing endoscopic procedures have an increased risk for aspiration pneumonia, according to a study...
Exercise Key to Maintaining Weight Loss After Stopping GLP-1 Receptor Agonists
MONDAY, March 4, 2024 – The addition of supervised exercise to obesity pharmacotherapy improves healthy weight maintenance after treatment termination, according to a study published online Feb. 19...
Liraglutide Exerts Weight Loss-Independent, GLP-1R-Dependent Effects
TUESDAY, Jan. 16, 2024 – Use of the glucagon-like peptide 1 receptor (GLP-1R) agonist liraglutide exerts weight loss-independent, GLP-1R-dependent effects on insulin sensitivity, according to a...
FDA Medwatch Alert: Drug Safety Communication: Certain Type of Medicines Approved for Type 2 Diabetes and Obesity - Update on FDA’s Ongoing Evaluation of Reports of Suicidal Thoughts or Actions
ISSUE: The FDA has been evaluating reports of suicidal thoughts or actions in patients treated with a class of medicines called glucagon-like peptide-1 receptor agonists (GLP-1 RAs; see the list in...
GI Adverse Events Increased With Use of GLP-1 Agonists for Weight Loss
FRIDAY, Oct. 6, 2023 – Use of glucagon-like peptide 1 (GLP-1) receptor agonists for weight loss is associated with increased risks for pancreatitis, gastroparesis, and bowel obstruction compared...
Racial, Ethnic Differences Seen for Benefits of Antihyperglycemic Agents
THURSDAY, Sept. 28, 2023 – There are racial/ethnic differences in the cardiorenal effects of sodium-glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide 1 receptor agonists...
FDA Approves Saxenda (liraglutide) for the Treatment of Obesity in Adolescents Aged 12-17
PLAINSBORO, N.J., Dec. 4, 2020 /PRNewswire/ -- Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) approved an updated label for Saxenda® (liraglutide) injection 3 mg for use...
FDA Approves Victoza (liraglutide) for the Treatment of Pediatric Patients 10 Years or Older with Type 2 Diabetes
June 17, 2019 – The U.S. Food and Drug Administration today approved Victoza (liraglutide) injection for treatment of pediatric patients 10 years or older with type 2 diabetes. Victoza is the first...
Victoza (liraglutide) is Approved to Reduce the Risk of Three Major Adverse Cardiovascular Events in Type 2 Diabetes Patients
PLAINSBORO, N.J., Aug. 25, 2017 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) has approved a new indication for Victoza (liraglutide) to reduce the risk of major adverse cardiovascular...
Novo Nordisk Receives FDA Approval for Xultophy 100/3.6 (insulin degludec and liraglutide injection) for Type 2 Diabetes
PLAINSBORO, N.J., Nov. 21, 2016 /PRNewswire/ – Novo Nordisk, a world leader in diabetes care, today announced that the U.S. Food and Drug Administration (FDA) approved the New Drug Application for...
FDA Medwatch Alert: Incretin Mimetic Drugs for Type 2 Diabetes: Early Communication - Reports of Possible Increased Risk of Pancreatitis and Pre-cancerous Findings of the Pancreas
ISSUE: FDA is evaluating unpublished new findings by a group of academic researchers that suggest an increased risk of pancreatitis and pre-cancerous cellular changes called pancreatic duct...
Victoza Label Updated to Include Data Showing Superior Efficacy When Compared to Januvia
Princeton, N.J. (April 9, 2012) /PRNewswire/ - Novo Nordisk received approval from the U.S. Food and Drug Administration (FDA) to update the product label for Victoza (liraglutide [rDNA origin]...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Weight Loss (Obesity / Overweight), Cardiovascular Risk Reduction, Diabetes, Type 2